Supernus Pharmaceuticals SUPN Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Supernus Pharmaceuticals's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Supernus Pharmaceuticals's retained earnings?
- Supernus Pharmaceuticals (SUPN) reported retained earnings of $515.58M in Q1 2026.
- How has Supernus Pharmaceuticals's retained earnings changed year-over-year?
- Supernus Pharmaceuticals's retained earnings decreased by 5.3% year-over-year, from $544.6M to $515.58M.
- What is the long-term trend for Supernus Pharmaceuticals's retained earnings?
- Over 5 years (2020 to 2025), Supernus Pharmaceuticals's retained earnings has grown at a 9.7% compound annual growth rate (CAGR), from $326.5M to $517.88M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.